DNA甲基化异常与肿瘤耐药  

Aberrant DNA methylation and drug resistance of tumor cells

作　　者：司鑫鑫 孙玉洁[1] 

机构地区：[1]江苏省人类功能基因组学重点实验室,南京医科大学基础医学院细胞生物学系,南京210029

出　　处：《遗传》2014年第5期411-419,共9页Hereditas（Beijing)

基　　金：国家自然科学基金项目(编号:81172091);江苏省普通高校研究生科研创新计划项目(编号:CXZZ13_0561)资助

摘　　要：肿瘤耐药是导致肿瘤化疗失败的主要原因,其产生机制复杂多样,是多种因素共同作用的结果。近年来,表观遗传改变在肿瘤耐药中的作用日益受到关注。DNA甲基化是一种重要的表观遗传修饰,在调节基因表达和维持基因组稳定性中扮演着重要角色。原发性或获得性耐药的肿瘤细胞大多伴随DNA异常甲基化,越来越多的证据显示,DNA甲基化异常是肿瘤细胞耐药表型产生的重要机制。文章就DNA甲基化异常与肿瘤细胞耐药的关系及相关作用机制进行了综述。Drug resistance is one of the major obstacles limiting the success of cancer chemotherapy. The underlying mechanisms are complex. In recent years, the contribution of epigenetic changes to drug resistance has drawn increasing attention. DNA methylation is an important epigenetic modification that plays an important role in regulating gene expres-sion and maintaining genome stability. Primary or acquired resistance of tumor cells is usually accompanied by aberrant DNA methylation. Accumulating evidence has shown that aberrant DNA methylation is involved in drug resistance of tu-mor cells. In this review, we briefly review the relationship between DNA methylation and drug resistance of tumor cells as well as the underlying mechanisms.

关 键 词：肿瘤耐药 DNA甲基化 基因组稳定性 基因表达 

分 类 号：Q75[生物学—分子生物学]